“We're at an important time for dementia. This is a time bomb. This is a terrible condition. We need to be doing more about this than in the past. Never has the health service and social care system been so fragile as it is today.” - Dame Gill Morgan NHS Providers (Chair)
Dementia, of which Alzheimer’s disease is the primary manifestation, is one of the most common and serious disorders faced by an increasingly aging population. It causes irreversible decline in global intellectual and physical functioning, progressive decline in memory, reasoning, communication skills and the ability to carry out daily activities as well as behavioural and psychological symptoms.
This also has profound, negative effects on family members. Family carers are often old and frail themselves and have high levels of carer burden, depression and physical illness.
The Pharmaceutical Industry’s revenues for 2013 reached $950 billion and are expected to surpass $1.2 trillion by the end of 2016. But in the under-served area of dementia, even though the number of patients being diagnosed is rising dramatically, the lack of any effective treatment means that the global market for Alzheimer's disease, which reached $10.2 billion in 2012, is expected to decrease at a compound annual growth rate of -1.5% to reach $9.5 billion in 2017 unless a safe and effective new treatment can be discovered and authorised.
The exponential rise in the number of patients presenting with Alzheimer's disease in the coming years, represents a significant market opportunity for therapeutics.
A novel, effective Alzheimer’s therapeutic product such as AIMSPRO, once regulated, could become one of the treatment options for patients suffering with this debilitating disease.